$SLS SLS huge upcoming catalysts that will cause $GLSI type movement 1Q earnings. They boosted their COH (cash on hand) to just over 35 million during 4Q. Also have a 200 million (plus royalties) licensing deal over 3 years. 2 year trial data of our drug in combination with MRK's Keytruda which ended in Dec of 2020 should be published any day. Investor conference was March 17th. More publicity and exposure. Very attractive stock! It has a very low float and severely undervalued market cap. Massive demand will meet no supply = rockets